Disc Medicine, Inc
DISC-1459
Erythropoietic Protoporphyria (EPP)
Countdown
86days
Phase 3 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 3 trial results for DISC-1459 in Erythropoietic Protoporphyria (EPP) are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT06910358: Phase 3 trial, sponsor Disc Medicine, Inc, drug DISC-1459. Primary completion date 2026-09 (estimated).”